Quince Therapeutics renames to IRulya and changes ticker symbol
The company relaunches as IRulya Therapeutics, focusing on LAM-001 for pulmonary diseases, with new leadership and a Nasdaq ticker of IRLA.
Latest Orphai Therapeutics News & Updates
See the latest news and media coverage for Orphai Therapeutics. We track all announcements, press releases, and industry mentions in real time, all in one place.
Biotechnology company developing inhaled treatments for serious pulmonary diseases
orphai-therapeutics.com- Headquarters
- New Haven, United States
- Founded year
- 2013
- Company type
- Private company
- Number of employees
- 2–25
- Industry
- Pharmaceuticals
Last updated
Latest news about Orphai Therapeutics
In short: Orphai Therapeutics merged with Quince, which rebranded as IRulya and raised $115M to advance LAM-001 pulmonary trials.
Company announcements
Orphai Therapeutics joins Quince in major acquisition
The transaction adds LAM-001 to Quince’s pipeline and provides upfront financing to fund Phase 2 trials through 2028.
Orphai Therapeutics acquired Quince announces LAM-001 Phase 2 data
Quince shows clinically meaningful improvements in lung function and hemodynamics for PH-ILD patients during the May 18 conference call and webcast.
Quce Therapeutics ceases clinical development of eDSP after failed Phase 3 trial
The NEAT Phase 3 trial for Ataxia-Telangiectasia missed statistical significance, leading the company to halt development and preserve cash while exploring other options.
Media coverage
Quince Relaunches as IRulya Therapeutics with New Leadership
Detailed price information for Quince Therapeutics Inc (QNCX-Q) from The Globe and Mail including charting and trades.
Quince Therapeutics to Participate in September 2026 Investor Conferences
Quince Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Update · Completed acquisition of Orphai Therapeutics, adding LAM-001, an inhaled formulation of rapamycin for...
Quince Announces Acquisition of Orphai and up to $187 Million Private Placement to Advance Pulmonary Pipeline
Acquisition includes LAM-001, an inhaled formulation of rapamycin for multiple pulmonary diseases, including pulmonary hypertension associated...
Orphai Therapeutics' Phase 2a LAM-001 Study Selected for Oral Presentation at the American Thoracic Society (ATS) 2026 International Conference
Orphai Therapeutics Inc. ("Orphai"), a clinical-stage biopharmaceutical company dedicated to advancing novel therapeutics for patients with diseases of significant unmet need, today announced that results...
Never miss news about Orphai Therapeutics
Track Orphai Therapeutics and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Orphai Therapeutics competitors & trending companies
Browse news for competitors to Orphai Therapeutics and other trending companies.
Gossamer Bio
Dillard Door
Optis
H2O Care Partners
AXN
Hueman
Shore
QatarEnergy
MET
Flex LNG
Celsius
JERA
SHI
Nordic Outdoor Group
Schwab
Alaunos Therapeutics
Liquidia
Spring Labs
Immediate
Bane NOR Eiendom
FagerStad
Aspelin Reitan
Entra
Thon
OBOS
Vedal
Selvaag
Solon
Neurophos
Opticore
Perficient
Coforge
Mastek
Birlasoft
Zensar
Apps